Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TARA Biosystems
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
TARA Biosystems provides induced pluripotent stem cell-derived 3D human cardiac tissue models and disease models (e.g., LMNA-associated cardiac laminopathies) for preclinical drug discovery, target validation, efficacy testing, and cardiotoxicity assessment; it does not market its own clinical-stage therapeutics but serves as an enabling platform for cardiovascular R&D.[1][2][5]
- Therapeutic areas
- Cardiovascular
- Modalities
- Small moleculeBiologicInduced pluripotent stem cell derived therapyCell therapy
- Industry
- Non-Drug Biotech
02
Partnerships
Valo Health (acquirer and integrated R&D partner)[2][4]Scipher Medicine (target discovery and validation partnership for cardiac laminopathies)[5]
Beyond the preview
Go deeper on TARA Biosystems.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TARA Biosystems.